Abstract: Primary hepatocarcinoma is one of the most common malignancies in clinic， of which the most common pathological type is hepatocellular carcinoma（HCC）. Sorafenib is the first and also the only molecular targeted drug approved in many countries for the treatment of HCC， but its efficacy is limited. After taking the drug for a period， most patients emerge disease progression because of resistance to the drug. Currently， the standard secondline treatment isn't available for these patients. This article reviews the latest research progress of secondline therapy for the HCC patients resisting to sorafenib.